Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 April 2004Website:
http://www.cytokinetics.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | 12 min agoDividend
Analysts recommendations
Institutional Ownership
CYTK Latest News
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2024 it granted stock options to purchase an aggregate of 17,712 shares of common stock and 11,499 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 7 employees, whose employment commenced in October 2024, as a material inducement to their employment.
NDA for Aficamten Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil, and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4 Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM Beyond The Heart” for Health Care Professionals SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) will provide an update on the company's cardiac myosin modulation programs and global commercial launch readiness for aficamten at its Investor and Analyst Day, “Heart Forward: Advancing Cardiac Myosin Modulation,” today at 8:30 AM Eastern Time in New York and streamed live online.
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2024 it granted stock options to purchase an aggregate of 88,653 shares of common stock and 57,558 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 30 employees, whose employment commenced in September 2024, as a material inducement to their employment.
Responder Analyses Show Treatment with Aficamten Demonstrated Improvements on Multiple Assessments of Clinical Significance to Cardiologists
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases
Monday, Cytokinetics, Incorporated CYTK announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session at the American College of Clinical Pharmacology Annual Meeting in Bethesda, MD.
Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024
Full Data from Phase 1 Study of CK-4021586 to be Presented on September 8, 2024 Full Data from Phase 1 Study of CK-4021586 to be Presented on September 8, 2024
Data from Integrated Safety Analysis Across Three Clinical Trials Reinforces Robust Safety Profile of Aficamten
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodeling by Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography, Symptom Relief and Improvement in Biomarkers with Aficamten
What type of business is Cytokinetics Incorporated?
Cytokinetics Inc. is a late-stage biopharmaceutical company. The company is focused on the discovery, development, and commercialization of first-in-class muscle activators as potential treatments for debilitating diseases where muscle performance is decreased and/or diminished. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and disorders. The company is developing small molecule drug candidates specifically designed to enhance muscle function and contractility. Cytokinetics, Inc. was founded in 1997, and its headquarters are located in South San Francisco, California.
What sector is Cytokinetics Incorporated in?
Cytokinetics Incorporated is in the Healthcare sector
What industry is Cytokinetics Incorporated in?
Cytokinetics Incorporated is in the Biotechnology industry
What country is Cytokinetics Incorporated from?
Cytokinetics Incorporated is headquartered in United States
When did Cytokinetics Incorporated go public?
Cytokinetics Incorporated initial public offering (IPO) was on 30 April 2004
What is Cytokinetics Incorporated website?
https://www.cytokinetics.com
Is Cytokinetics Incorporated in the S&P 500?
No, Cytokinetics Incorporated is not included in the S&P 500 index
Is Cytokinetics Incorporated in the NASDAQ 100?
No, Cytokinetics Incorporated is not included in the NASDAQ 100 index
Is Cytokinetics Incorporated in the Dow Jones?
No, Cytokinetics Incorporated is not included in the Dow Jones index
When was Cytokinetics Incorporated the previous earnings report?
No data
When does Cytokinetics Incorporated earnings report?
Next earnings report date is not announced yet